Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gene therapy |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
2020 |
| gptkbp:ATCCode |
L01XL10
|
| gptkbp:brand |
gptkb:Tecartus
|
| gptkbp:developer |
gptkb:Kite_Pharma
|
| https://www.w3.org/2000/01/rdf-schema#label |
brexucabtagene autoleucel
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
CD19-directed genetically modified autologous T cell immunotherapy
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
cytokine release syndrome
neurologic toxicities |
| gptkbp:target |
gptkb:CD19
|
| gptkbp:usedFor |
gptkb:mantle_cell_lymphoma
leukemia |
| gptkbp:bfsParent |
gptkb:Tecartus
|
| gptkbp:bfsLayer |
6
|